NCT02267980

Brief Summary

The investigators evaluate the effects of a subanesthetic dose of ketamine, administered as an adjunct to sevoflurane, on duration of seizure activity, hemodynamic profile and recovery times during electroconvulsive therapy (ECT) in patients with major depression.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Jul 2014

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2014

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2014

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

October 9, 2014

Completed
11 days until next milestone

First Posted

Study publicly available on registry

October 20, 2014

Completed
Last Updated

October 20, 2014

Status Verified

October 1, 2014

Enrollment Period

3 months

First QC Date

October 9, 2014

Last Update Submit

October 15, 2014

Conditions

Keywords

Electroconvulsive therapy; sevoflurane; ketamine

Outcome Measures

Primary Outcomes (1)

  • seizure duration

    the time from application of the ECT stimulus to the cessation of tonic-clonic motor activity in the isolated arm.

    During electroconvulsive therapy (30 minutes)

Secondary Outcomes (2)

  • Mean arterial pressure (MAP)

    During Electroconvulsive therapy (30 minutes)

  • Heart rate (HR)

    During Electroconvulsive therapy (30 minutes)

Study Arms (2)

Group SK

ACTIVE COMPARATOR

Sevoflurane was initiated, in both groups, at 8% for anesthesia induction until loss of consciousness was achieved, at which point it was discontinued. Following loss of consciousness ketamine was administered to Group SK (n=29) in the form of a 0.5mg/kg iv bolus. Patients in Group SS (n=30) received saline in the same manner.

Drug: SevofluraneDrug: Ketamine

Group SS

PLACEBO COMPARATOR

Sevoflurane was initiated, in both groups, at 8% for anesthesia induction until loss of consciousness was achieved, at which point it was discontinued. Patients in Group SS (n=30) received saline in the same manner.

Drug: SevofluraneDrug: Saline

Interventions

Inhalation anesthetic agent

Also known as: Sevoflurane (sevorane)
Group SKGroup SS

Intravenous anesthetic agent

Also known as: Ketamine (Ketalar) 50mg/mL injection
Group SK
SalineDRUG

Isotonic solution for placebo group

Also known as: Isotonic solution
Group SS

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Major depressive patients

You may not qualify if:

  • Pregnancy
  • Have a history of myocardial infarction in the previous six months
  • Atrial fibrillation or flutter
  • Heart block
  • Unregulated hypertension
  • Cerebrovascular diseases
  • A known drug allergy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Turgut Ozal Medical Center

Malatya, 44315, Turkey (Türkiye)

RECRUITING

Related Publications (1)

  • Yalcin S, Aydogan H, Selek S, Kucuk A, Yuce HH, Karababa F, Bilgic T. Ketofol in electroconvulsive therapy anesthesia: two stones for one bird. J Anesth. 2012 Aug;26(4):562-7. doi: 10.1007/s00540-012-1378-6. Epub 2012 May 24.

MeSH Terms

Conditions

Depressive Disorder

Interventions

SevofluraneKetamineInjectionsSodium ChlorideIsotonic Solutions

Condition Hierarchy (Ancestors)

Mood DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Methyl EthersEthersOrganic ChemicalsHydrocarbons, FluorinatedHydrocarbons, HalogenatedHydrocarbonsCyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicDrug Administration RoutesDrug TherapyTherapeuticsChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium CompoundsSolutionsPharmaceutical Preparations

Study Officials

  • Feray Erdil, MD

    MD

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associated Professor

Study Record Dates

First Submitted

October 9, 2014

First Posted

October 20, 2014

Study Start

July 1, 2014

Primary Completion

October 1, 2014

Study Completion

October 1, 2014

Last Updated

October 20, 2014

Record last verified: 2014-10

Locations